Physician profile
Robert Quick
NPI 1255868196
$773.83
in general payments reported to CMS, 2019-2025
18 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.45 · 2020: $36.28 · 2021: $135 · 2022: $167 · 2023: $161 · 2024: $154 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $167.55 | 2020-2025 | |
| Abbvie INC. | $126.18 | 2021-2023 | |
| Amgen INC. | $86.66 | 2024-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $68.85 | 2020-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $44.50 | 2022-2024 | Farxiga |
| Lilly USA, LLC | $35.05 | 2021-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $31.43 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $28.97 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.01 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $25.49 | 2024 | Rexulti |
| Abbott Laboratories | $20.97 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $17.48 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.44 | 2023 | Xifaxan |
| Amarin Pharma, INC. | $16.72 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.95 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.76 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $13.96 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.86 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Quick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.